CAPR Court Alert: Capricor Therapeutics Securities Fraud Class Action Deadline is Approaching on September 28 for Investors that Suffered Losses
DeramiocelNegative
AI Analysis
Summary
Capricor Therapeutics faces a securities fraud class action lawsuit alleging misstatements regarding Deramiocel and clinical data supporting its BLA, resulting in a 64% stock decline. The class action deadline is September 28, 2026.
Outcome Details
Securities fraud class action lawsuit alleging misstatements about Deramiocel and clinical data integrity supporting BLA
Importance:8/10
Sentiment:
-0.95
securities fraudclass action lawsuitBLAdata integritystock decline
Related Companies
Read the original article
Published by PR Newswire Biotech on September 15, 2026 10:37 AM